Literature DB >> 7684863

Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.

J J Bolger1, D P Dearnaley, D Kirk, V J Lewington, M D Mason, P M Quilty, N S Reed, J M Russell, J Yardley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7684863

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  9 in total

Review 1.  Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.

Authors:  Michael J Morris; Neeta Pandit-Taskar; Chaitanya Divgi; Steven Larson; Howard I Scher
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

Review 2.  WITHDRAWN: Radiotherapy for the palliation of painful bone metastases.

Authors:  Henry J McQuay; Sally L Collins; Dawn Carroll; R Andrew Moore; Sheena Derry
Journal:  Cochrane Database Syst Rev       Date:  2013-11-22

Review 3.  Bone pain and radionuclide therapy.

Authors:  P Vande Streek; R Carretta; F L Weiland
Journal:  West J Med       Date:  1994-10

Review 4.  The pathophysiology and management of spine metastasis from lung cancer.

Authors:  J S Greenberger
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

5.  Radionuclide Therapy of Bone Metastases.

Authors:  Manfred Fischer; Willm U Kampen
Journal:  Breast Care (Basel)       Date:  2012-04-24       Impact factor: 2.860

6.  Palliative effects and adverse events of strontium-89 for prostate cancer patients with bone metastasis.

Authors:  Nobuki Furubayashi; Takahito Negishi; Shintaro Ura; Yoshiki Hirai; Motonobu Nakamura
Journal:  Mol Clin Oncol       Date:  2014-10-30

Review 7.  Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

Authors:  Howard I Scher; Michael J Morris; William K Kelly; Lawrence H Schwartz; Glenn Heller
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

Review 8.  Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.

Authors:  Michael J Morris; Neeta Pandit-Taskar; Chaitanya Divgi; Steven Larson; Howard I Scher
Journal:  Curr Urol Rep       Date:  2005-05       Impact factor: 2.862

Review 9.  Current approaches, challenges and future directions for monitoring treatment response in prostate cancer.

Authors:  T J Wallace; T Torre; M Grob; J Yu; I Avital; Bldm Brücher; A Stojadinovic; Y G Man
Journal:  J Cancer       Date:  2014-01-01       Impact factor: 4.207
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.